Alhydrogel In Marketed Vaccines

Lab Reagents

Alphabioregen Laboratories manufactures the alhydrogel in marketed vaccines reagents distributed by Genprice. The Alhydrogel In Marketed Vaccines reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Alphabioregen. Other Alhydrogel products are available in stock. Specificity: Alhydrogel Category: In Group: Marketed Vaccines

Marketed Vaccines information

BMX-IN-1
A3260-50 50 mg
EUR 1437.6
Description: BMX-IN-1 is a highly selective and irreversible inhibitor of BMX kinase [1].BMX, also known as ETK, is a member of Tec family and plays an important role in regulating ischemia-mediated arteriogenesis and lymphangiogenesis

JNK-IN-7
A3519-10 10 mg
EUR 572.4
Description: JNK-IN-7 is a selective JNK inhibitor with IC50 values of 1.54 nM, 1.99 nM, 0.75 nM to JNK1, JNK2, JNK3, respectively. It also inhibits phosphorylation of c-Jun, which is a direct substrate of JNK kinase.

JNK-IN-7
A3519-100 100 mg
EUR 2270.4
Description: JNK-IN-7 is a selective JNK inhibitor with IC50 values of 1.54 nM, 1.99 nM, 0.75 nM to JNK1, JNK2, JNK3, respectively. It also inhibits phosphorylation of c-Jun, which is a direct substrate of JNK kinase.

JNK-IN-7
A3519-5 5 mg
EUR 459.6
Description: JNK-IN-7 is a selective JNK inhibitor with IC50 values of 1.54 nM, 1.99 nM, 0.75 nM to JNK1, JNK2, JNK3, respectively. It also inhibits phosphorylation of c-Jun, which is a direct substrate of JNK kinase.

JNK-IN-7
A3519-5.1 10 mM (in 1mL DMSO)
EUR 498
Description: JNK-IN-7 is a selective JNK inhibitor with IC50 values of 1.54 nM, 1.99 nM, 0.75 nM to JNK1, JNK2, JNK3, respectively. It also inhibits phosphorylation of c-Jun, which is a direct substrate of JNK kinase.

JNK-IN-7
A3519-50 50 mg
EUR 1448.4
Description: JNK-IN-7 is a selective JNK inhibitor with IC50 values of 1.54 nM, 1.99 nM, 0.75 nM to JNK1, JNK2, JNK3, respectively. It also inhibits phosphorylation of c-Jun, which is a direct substrate of JNK kinase.

JNK-IN-8
A3520-10 10 mg
EUR 309.6
Description: JNK-IN-8 is a specific JNK1/2/3 inhibitor with IC50 value of 4.67, 18.7, 0.98 nM respectively [1].

JNK-IN-8
A3520-5 5 mg
EUR 226.8
Description: JNK-IN-8 is a specific JNK1/2/3 inhibitor with IC50 value of 4.67, 18.7, 0.98 nM respectively [1].

JNK-IN-8
A3520-5.1 10 mM (in 1mL DMSO)
EUR 271.2
Description: JNK-IN-8 is a specific JNK1/2/3 inhibitor with IC50 value of 4.67, 18.7, 0.98 nM respectively [1].

JNK-IN-8
A3520-50 50 mg
EUR 811.2
Description: JNK-IN-8 is a specific JNK1/2/3 inhibitor with IC50 value of 4.67, 18.7, 0.98 nM respectively [1].

LRRK2-IN-1
A3558-10 10 mg
EUR 177.6
Description: LRRK2-IN-1 is a potent and selective inhibitor of LRRK2 with IC50 value of 13 nM. [1]LRRK2 (Leucine-rich repeat kinase 2) is also known dardarin. LRRK2 belongs to the leucine-rich repeat kinase family.

LRRK2-IN-1
A3558-100 100 mg
EUR 714
Description: LRRK2-IN-1 is a potent and selective inhibitor of LRRK2 with IC50 value of 13 nM. [1]LRRK2 (Leucine-rich repeat kinase 2) is also known dardarin. LRRK2 belongs to the leucine-rich repeat kinase family.

LRRK2-IN-1
A3558-5.1 10 mM (in 1mL DMSO)
EUR 236.4
Description: LRRK2-IN-1 is a potent and selective inhibitor of LRRK2 with IC50 value of 13 nM. [1]LRRK2 (Leucine-rich repeat kinase 2) is also known dardarin. LRRK2 belongs to the leucine-rich repeat kinase family.

LRRK2-IN-1
A3558-50 50 mg
EUR 505.2
Description: LRRK2-IN-1 is a potent and selective inhibitor of LRRK2 with IC50 value of 13 nM. [1]LRRK2 (Leucine-rich repeat kinase 2) is also known dardarin. LRRK2 belongs to the leucine-rich repeat kinase family.

Jnk-In-7
20-abx184143
  • EUR 1144.80
  • EUR 760.80
  • 10 mg
  • 5 mg

TMPRSS2 (IN) Antibody
9571-002mg 0.02 mg
EUR 229.7
Description: TMPRSS2 Antibody: TMPRSS2 is a plasma membrane-anchored serine protease that participates in proteolytic cascades of relevance for the normal physiologic function of the prostate. Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells. It facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via two independent mechanisms, proteolytic cleavage of ACE2 receptor which promotes viral uptake, and cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry. It proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). TMPRSS2 is essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9), and it is involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity.

TMPRSS2 (IN) Antibody
9571-01mg 0.1 mg
EUR 594.26
Description: TMPRSS2 Antibody: TMPRSS2 is a plasma membrane-anchored serine protease that participates in proteolytic cascades of relevance for the normal physiologic function of the prostate. Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells. It facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via two independent mechanisms, proteolytic cleavage of ACE2 receptor which promotes viral uptake, and cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry. It proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). TMPRSS2 is essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9), and it is involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity.